Justin Kuepper
Long only, deep value, special situations, event-driven

Cambrex: Discounted Valuation And Upcoming Catalysts

Cambrex Corporation (NYSE: CBM) is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics. While the stock has risen some 34% year to date, the company's discounted valuation and upcoming catalysts could suggest greater upside ahead. In this article, we will take a look at both of these drivers in greater detail.

A Brief Primer

Cambrex generates the majority of its revenues from custom development and manufacturing (45%), with generics (36%), control substances (14%) and drug delivery (5%) rounding out its business. With R&D and cGMP manufacturing facilities in the U.S., Europe and India, the company provides APIs, advanced intermediates, drug delivery products and custom development...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details